November 2024

14
Nov
Thu, 11/14/2024 - 00:00
OTHER EVENT

Carolinas Day of Education 2024

Thursday, Nov. 14 from 8am–4pm ET

November 2024

14
Nov
Thu, 11/14/2024 - 00:00
WEBINAR

Overview of an Adjunctive Treatment for Major Depressive Disorder

A Science & Innovation Webinar, presented by Abbvie.

Major Depressive Disorder (MDD) is a disabling mental health condition with an annual prevalence of 10.4% and a lifetime prevalence of 20.6% in the US. This is associated with a high economic burden, which has increased significantly over the last decade, comprising direct and indirect costs, due to lost productivity. MDD also results in considerable burden to patients, with social, emotional and physical problems; cognitive difficulties; changes in sleep and eating patterns; and can impact patients’ quality of life.  Many MDD patients require augmentation of their antidepressant with an additional therapy, and augmentation with an atypical antipsychotic is a guideline-recommended option for appropriate MDD patients. This session will focus on the burden of MDD, as well as the pharmacology, efficacy, and safety of an adjunctive treatment for MDD.

Thursday, Nov. 14, 2024 | 2–3pm ET

November 2024

14
Nov
Thu, 11/14/2024 - 00:00
WEBINAR

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program: 2027 and Beyond

An AMCP Webinar.

In this one-hour webinar we will dive deep into CMS’ recently finalized negotiation guidance for Initial Price Applicability Year (IPAY) 2027, exploring how CMS has proposed to modify the negotiation program in its second year. We will also explore how manufacturers of drugs selected for both IPAY 2026 and 2027 will make their drugs available to Medicare beneficiaries and dispensing entities at the negotiated maximum fair price, including through two separate functions provided by a Medicare Transaction Facilitator (MTF). Lastly, we will touch briefly on recent litigation developments challenging the negotiation program.

Thursday, Nov. 14, 2024 | 12–1pm ET

November 2024

13
Nov
Wed, 11/13/2024 - 00:00
WEBINAR

Redefining Treatment for Hypoparathyroidism in Adults: When Patients Are Inadequately Controlled on Conventional Therapy

A Science & Innovation Webinar, presented by Ascendis.

Addressing gaps in patient care for adults with hypoparathyroidism with reliable treatment beyond conventional therapy.

Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH). PTH is the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidneys and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for approximately 75% of cases, while other etiologies include autoimmune and idiopathic causes.

There is a lack of treatment options for hypoparathyroidism in adults. Conventional therapy consists of oral calcium and active vitamin D, and aims to alleviate hypocalcemia but does not address insufficient parathyroid hormone (PTH). This can lead to a wide range of both short- and long-term complications.

Wednesday, Nov. 13, 2024 | 2–3pm ET

November 2024

12-13
Nov
2024
OTHER EVENT

Partnership Forum – Closing the Gap in Real-World Evidence Use: A Collaborative Approach for Health Care Transformation

Real-world evidence (RWE) is increasingly used to support epidemiologic studies, safety and effectiveness studies, and even contribute to clinical trials or as evidence included in regulatory submissions. However, RWE has a much less prominent role in payer decision-making, particularly due to challenges such as a lack of standards and guidelines for how to evaluate and use RWE, lack of experience in applying RWE to formulary decisions, and lack of understanding how RWE could be most impactful for payer decisions. AMCP is developing standards and resources to support RWE interpretation and application to formulary and medical policy decisions. These standards aim to align RWE definitions, improve the transparency in RWE generation, increase consistency in how sponsors develop and share RWE, and support the ongoing communication between payers and pharmaceutical manufacturers. 

This Partnership Forum will convene multi-stakeholder experts to develop resources that will address barriers to RWE use in formulary decision-making through workshop and collaborative activities that will result in a set of RWE standards and tools to facilitate stakeholder communication and streamline the use of RWE. This is an invite-only event.

Washington, DC

November 2024

7
Nov
Thu, 11/07/2024 - 00:00
OTHER EVENT

Mid-South AMCP Biosimilar Implementation

Thursday, Nov. 7, 2024 | 6–8:30pm CT

November 2024

7
Nov
Thu, 11/07/2024 - 00:00
WEBINAR

Application of Indirect Treatment Comparisons

A Science & Innovation Webinar, presented by Abbvie.

The intent of evidence-based health care decision making is to compare all applicable and available treatment options. When direct comparisons from randomized controlled trials are not available, indirect treatment comparisons, including network meta-analyses, may offer valuable insights. In addition, mixed treatment comparisons, a type of network meta-analysis, combine both direct and indirect evidence for specific comparisons, providing a broader view than traditional network meta analysis.

Thursday, Nov. 7, 2024 | 12–1pm ET

November 2024

6
Nov
Wed, 11/06/2024 - 00:00
WEBINAR

A Preventive Treatment Option for Adults with Migraine

A Science & Innovation Webinar, presented by Abbvie.

Migraine is a complex, chronic disease that results in significant patient and economic burden. It is important to appropriately manage a person with migraine who experiences greater than 4 attacks a month (or severe disability from at least two attacks a month) and may benefit from preventive therapy. One of the main goals of preventive therapy is to improve function and reduce disability. Utilizing a stratified care approach to preventive migraine treatment is key to accomplish this goal. During this webinar, a migraine expert will discuss the complexity of migraine disease and the burden of the disease as it relates to function, and the treatment landscape, with a focus on a preventive treatment option for adults with migraine.

Wednesday, Nov. 6, 2024 | 12–1pm ET

November 2024

4
Nov
Mon, 11/04/2024 - 00:00
WEBINAR

A Novel, Once Daily Oral Tablet Being Investigated as the First Treatment for Hyperphagia in Prader-Willi Syndrome (PWS)

A Pre-Approval Information Exchange (PIE) Webinar, presented by Soleno Therapeutics.

Soleno Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of a novel therapy to treat Hyperphagia in Prader-Willi syndrome (PWS), a rare and life-threatening neurobehavioral, metabolic and endocrine disorder characterized by hyperphagia, neurocognitive and behavioral difficulties. The company is currently pursuing regulatory approval in the United States for its lead investigational candidate, DCCR (diazoxide choline) extended-release tablets.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

Monday, November 4, 2024 | 2–3pm ET

November 2024

1
Nov
Fri, 11/01/2024 - 00:00
OTHER EVENT

Steven G. Avey Award Application Deadline

The Steven G. Avey Award recognizes a health care professional for sustained, exemplary and distinguished service to the practice of managed care pharmacy.

Nominate a deserving individual who has made meaningful and impactful contributions to the field today!

Applications Close Nov. 1, 2024